Cardiovascular disease in Sickle cell: mechanisms, diagnostics and therapeutic advances.

IF 4.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Heart Pub Date : 2025-08-07 DOI:10.1136/heartjnl-2025-325837
Elio Haroun, Ankit Agrawal, Aro Daniela Arockiam, Joseph El Dahdah, Joseph Kassab, Michael Nakhla, Michel Chedid El Helou, Harsha Sanaka, Ziad Zalaquett, Simrat Kaur, Tiffany Dong, Rabi Hanna, Brian Griffin, Tom Kai Ming Wang
{"title":"Cardiovascular disease in Sickle cell: mechanisms, diagnostics and therapeutic advances.","authors":"Elio Haroun, Ankit Agrawal, Aro Daniela Arockiam, Joseph El Dahdah, Joseph Kassab, Michael Nakhla, Michel Chedid El Helou, Harsha Sanaka, Ziad Zalaquett, Simrat Kaur, Tiffany Dong, Rabi Hanna, Brian Griffin, Tom Kai Ming Wang","doi":"10.1136/heartjnl-2025-325837","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular complications are increasingly recognised as a major driver of morbidity and early mortality in patients with sickle cell disease (SCD), yet they remain underdiagnosed and underappreciated. This contemporary review synthesises current knowledge across a spectrum of cardiovascular manifestations-including myocardial dysfunction, pulmonary hypertension, cardiac iron overload, arrhythmias, myocardial infarction, stroke and sudden death-with emphasis on their unique pathophysiological mechanisms in SCD. We highlight emerging diagnostic tools such as cardiac magnetic resonance with T2* mapping and extracellular volume sequences, speckle-tracking echocardiography and invasive exercise testing, which can revealing a distinct phenotype combining restrictive cardiomyopathy and high-output heart failure. Practical algorithms for risk stratification and disease monitoring are presented alongside evidence-based and SCD-specific management approaches, including the role of hydroxyurea, transfusions, anticoagulation and gene therapy. By integrating multimodality imaging, updated guideline recommendations and recent clinical insights, this review provides a comprehensive resource to support early recognition, personalised therapy and improved cardiovascular outcomes in SCD.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/heartjnl-2025-325837","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiovascular complications are increasingly recognised as a major driver of morbidity and early mortality in patients with sickle cell disease (SCD), yet they remain underdiagnosed and underappreciated. This contemporary review synthesises current knowledge across a spectrum of cardiovascular manifestations-including myocardial dysfunction, pulmonary hypertension, cardiac iron overload, arrhythmias, myocardial infarction, stroke and sudden death-with emphasis on their unique pathophysiological mechanisms in SCD. We highlight emerging diagnostic tools such as cardiac magnetic resonance with T2* mapping and extracellular volume sequences, speckle-tracking echocardiography and invasive exercise testing, which can revealing a distinct phenotype combining restrictive cardiomyopathy and high-output heart failure. Practical algorithms for risk stratification and disease monitoring are presented alongside evidence-based and SCD-specific management approaches, including the role of hydroxyurea, transfusions, anticoagulation and gene therapy. By integrating multimodality imaging, updated guideline recommendations and recent clinical insights, this review provides a comprehensive resource to support early recognition, personalised therapy and improved cardiovascular outcomes in SCD.

镰状细胞性心血管疾病:机制、诊断和治疗进展。
心血管并发症越来越被认为是镰状细胞病(SCD)患者发病和早期死亡的主要驱动因素,但它们仍未得到充分诊断和重视。这篇当代综述综合了心血管表现的最新知识,包括心肌功能障碍、肺动脉高压、心铁超载、心律失常、心肌梗死、中风和猝死,重点是它们在SCD中独特的病理生理机制。我们重点介绍了新兴的诊断工具,如心脏磁共振T2*制图和细胞外体积序列,斑点跟踪超声心动图和侵入性运动测试,这些工具可以揭示限制性心肌病和高输出心力衰竭的独特表型。风险分层和疾病监测的实用算法与循证和scd特异性管理方法一起提出,包括羟基脲的作用、输血、抗凝和基因治疗。通过整合多模态影像、最新的指南建议和最新的临床见解,本综述为支持SCD的早期识别、个性化治疗和改善心血管结局提供了全面的资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Heart
Heart 医学-心血管系统
CiteScore
10.30
自引率
5.30%
发文量
320
审稿时长
3-6 weeks
期刊介绍: Heart is an international peer reviewed journal that keeps cardiologists up to date with important research advances in cardiovascular disease. New scientific developments are highlighted in editorials and put in context with concise review articles. There is one free Editor’s Choice article in each issue, with open access options available to authors for all articles. Education in Heart articles provide a comprehensive, continuously updated, cardiology curriculum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信